Dr. Malone Quits ACIP Vaccine Advisory Panel Over Internal Drama
Dr. Robert Malone, vice chair of ACIP, angrily resigned his position on Tuesday, citing a dispute with HHS spokesperson Andrew Nixon over press statements, saying "After Andrew trashing me with the press, I am done with the CDC and ACIP. That was the last straw."
Objective Facts
Robert Malone, vice chair of the federal committee that recommends vaccines to Americans, angrily resigned his position on Tuesday. He is stepping away from a panel of federal vaccine advisers after a federal judge blocked the panel's work. Malone said in a text message "After Andrew trashing me with the press, I am done with the CDC and ACIP," referring to HHS spokesman Andrew Nixon. Malone posted on social media that the decision wouldn't be appealed, which was contradicted by HHS spokeman Andrew Nixon. Malone was appointed to the Advisory Committee on Immunization Practices last year by Kennedy, who dismissed the previous panel because he said it was influenced by pharmaceutical interests. A federal judge sided with plaintiffs on March 16, 2026, ruling that Kennedy likely appointed 13 panelists in violation of FACA, effectively blocking those appointments.
Left-Leaning Perspective
Left-leaning and pro-vaccination outlets frame Malone's resignation as the departure of an unqualified ideologue whose panel was exposed as illegitimate. Crooks and Liars describes Malone as the "quackety-quack anti-vax vice chair" whose panel was blocked by a federal judge who ruled that the advisers "did not have the expertise needed to make vaccine recommendations." The Genetic Literacy Project headlines his resignation as occurring "after judge says he's not qualified," emphasizing judicial skepticism of his qualifications. These outlets cite Malone's history of questioning the severity of COVID-19 and elevating unfounded claims about the disease as evidence that removing him from power represents appropriate accountability. Legal scholars argue that Malone's appointment itself contradicts Kennedy's stated rationale about removing committee members with conflicts of interest, suggesting the rationale was disingenuous. A fellow ACIP member appointed by Kennedy, Joseph Hibbeln, told the Times that Malone's stated aversion to drama "contrasts with his prior dramatic and confusing statements." The left emphasizes that Malone acknowledged on a podcast that Republicans have become aware anti-vax actions will harm candidates, and the administration is "slow walking" any appeals of Judge Murphy's ruling. This framing suggests political calculation has replaced principled support for Malone and the panel's agenda.
Right-Leaning Perspective
Right-leaning or administration-aligned sources defend Nixon and the HHS response while allowing Malone to articulate his grievances without editorial judgment. Former ACIP Chair Martin Kulldorff defended Nixon as "professional and honest" and acknowledged Malone's decision to step away given the court ruling and volunteers' burden. Administration officials emphasize process and respect for service rather than challenging Malone's credentials. Malone argues he performed "hundreds of hours of uncompensated labor" amid "hostile press" and "sabotage," and disputes the judge's conclusion, saying the judge "completely overlooked my actual CV and experience." This framing presents Malone as a victim of institutional hostility rather than as unqualified. Right-aligned reporting notes that the committee had achieved significant changes before being "kneecapped by the courts," including removing recommendations for several childhood vaccines, which was "a priority for Kennedy and the 'Make America Healthy Again' movement." These sources treat Malone's grievances as substantive complaints about unfair treatment and institutional bias rather than as excuses by someone lacking qualification. The focus remains on the court's intervention and the political consequences rather than validating judicial skepticism of Malone's expertise.
Deep Dive
Malone's resignation occurs in the immediate aftermath of a federal judge's March 16 ruling that Kennedy likely violated FACA (the Federal Advisory Committee Act) by appointing 13 panelists without proper procedures, effectively blocking those appointments and putting the panel in judicial limbo. The proximate cause was Malone posting to social media that there would be no appeal of the judge's decision, only for HHS spokesman Andrew Nixon to contradict this statement publicly. Reports indicate a widening rift between Kennedy's anti-vaccine movement and the broader Trump administration, with the White House clamping down on HHS vaccine messaging after polling found Kennedy's moves unpopular with voters ahead of midterm elections. Each side has legitimate points. The left correctly notes that the judge raised questions about the panelists' expertise, particularly Malone's: his background in early mRNA research does not necessarily qualify him to make contemporary vaccine recommendations, and he has testified as an expert witness in vaccine litigation, which courts have scrutinized. The right correctly observes that even HHS Secretary Kennedy Jr. has not decided whether to appeal, disband the committee, or pursue another course, leaving institutional uncertainty. Malone's complaint about uncompensated labor and internal hostility is partially corroborated by fellow Kennedy-appointed ACIP member Joseph Hibbeln's acknowledgment of Malone's stated aversion to drama while noting it contradicts prior statements, suggesting genuine interpersonal friction on the panel. What remains unresolved is whether Malone's departure will accelerate administration retreat from vaccine policy changes or whether it will be treated as an isolated exit by one frustrated member. The future of ACIP remains uncertain, with reports suggesting the possibility of disbanding and reconstituting the committee, though HHS has not officially confirmed this course of action. Additionally, the extent to which political calculations about voter sentiment—rather than scientific judgment—are driving HHS decision-making on vaccine policy remains opaque and contested.